Abstract

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus, which affects both children and adults. Although most cases of COVID-19 in children have a mild course, sometimes the disease is severe. Multisystem inflammatory syndrome in children (MIS-C) is a rare complication of COVID-19, characterized by pronounced cardiovascular, gastrointestinal, and skin-mucosal signs and symptoms that, in particular, may meet the criteria for atypical or typical Kawasaki disease (KD). This article represents a clinical case of a 13-year-old boy with an atypical course of SARS-CoV-2- Induced Kawasaki-Like Multisystem Hyperinflammatory Syndrome, who was treated with intravenous immunoglobulin, corticosteroids, and aspirin. Equally, it presents a thorough description of carrying out a differential diagnosis between MIS-C and Kawasaki disease and a review of the application of drugs needed for MIS-C treatment, the main goal of which is to ensure the best protection against CA aneurysms and avoid long-term sequelae.

Keywords: Coronavirus disease (COVID-19); Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19; Kawasaki disease; Intravenous immunoglobulin (IVIG); Corticosteroids

Abbreviations:COVID-19: Coronavirus Disease 2019; SARS-CoV-2: Severe Acute Respiratory Syndrome; MIS-C: Multisystem Inflammatory Syndrome in Children; WHO: World Health Organization; CDC: Centers for Disease Control and Prevention; KD: Kawasaki Disease; PCR: Polymerase Chain Reaction; RNA: Ribonucleic Acid; ELISA: Enzyme-Linked Immunoassay; CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; CBC: Complete Blood Count; Echo-CG: Echocardiogram; TMA: Territorial Medical Association; ECG: Electrocardiogram; LV: Left Ventricle; IVIG: Intravenous Immunoglobulin; CA: Coronary Artery.